Zachary Scott Wallace, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 21 | 2023 | 220 | 11.050 |
Why?
|
Rheumatic Diseases | 35 | 2024 | 593 | 9.930 |
Why?
|
Antibodies, Antineutrophil Cytoplasmic | 14 | 2023 | 289 | 4.750 |
Why?
|
Antirheumatic Agents | 23 | 2024 | 1338 | 4.680 |
Why?
|
Autoimmune Diseases | 23 | 2023 | 2134 | 4.250 |
Why?
|
Rheumatology | 18 | 2023 | 576 | 3.470 |
Why?
|
Immunoglobulin G | 31 | 2024 | 4561 | 2.970 |
Why?
|
Peroxidase | 5 | 2023 | 611 | 2.460 |
Why?
|
Biological Products | 9 | 2021 | 860 | 1.880 |
Why?
|
Arthritis, Rheumatoid | 15 | 2024 | 3712 | 1.810 |
Why?
|
Kidney Failure, Chronic | 7 | 2023 | 2535 | 1.720 |
Why?
|
Glucocorticoids | 21 | 2023 | 2108 | 1.590 |
Why?
|
Plasma Cells | 7 | 2023 | 591 | 1.580 |
Why?
|
Vasculitis | 4 | 2023 | 519 | 1.430 |
Why?
|
Myeloblastin | 2 | 2019 | 101 | 1.380 |
Why?
|
Remission Induction | 10 | 2023 | 2385 | 1.060 |
Why?
|
Pneumonia, Pneumocystis | 2 | 2023 | 249 | 1.020 |
Why?
|
Polyarteritis Nodosa | 2 | 2022 | 66 | 0.990 |
Why?
|
Lupus Nephritis | 3 | 2022 | 310 | 0.930 |
Why?
|
Takayasu Arteritis | 2 | 2022 | 96 | 0.920 |
Why?
|
Polychondritis, Relapsing | 2 | 2013 | 28 | 0.900 |
Why?
|
Kidney Transplantation | 4 | 2022 | 4251 | 0.850 |
Why?
|
Retroperitoneal Fibrosis | 2 | 2019 | 38 | 0.830 |
Why?
|
Cyclophosphamide | 9 | 2023 | 2242 | 0.830 |
Why?
|
Deltoid Muscle | 1 | 2021 | 18 | 0.820 |
Why?
|
Receptors, Interleukin-6 | 2 | 2013 | 225 | 0.800 |
Why?
|
Giant Cell Arteritis | 2 | 2022 | 292 | 0.780 |
Why?
|
Immunosuppressive Agents | 9 | 2023 | 4153 | 0.780 |
Why?
|
Humans | 156 | 2024 | 744366 | 0.760 |
Why?
|
IgG Deficiency | 1 | 2020 | 28 | 0.740 |
Why?
|
Middle Aged | 74 | 2024 | 213390 | 0.730 |
Why?
|
Immunoglobulin Isotypes | 1 | 2020 | 158 | 0.710 |
Why?
|
Mikulicz' Disease | 1 | 2019 | 8 | 0.690 |
Why?
|
Dermatomyositis | 1 | 2021 | 224 | 0.680 |
Why?
|
Immunologic Factors | 9 | 2024 | 1580 | 0.670 |
Why?
|
Male | 87 | 2024 | 350115 | 0.640 |
Why?
|
Career Mobility | 1 | 2020 | 262 | 0.630 |
Why?
|
Otorhinolaryngologic Diseases | 1 | 2019 | 90 | 0.630 |
Why?
|
Aortitis | 1 | 2019 | 74 | 0.630 |
Why?
|
Hepatitis B virus | 2 | 2021 | 513 | 0.620 |
Why?
|
Female | 87 | 2024 | 380193 | 0.610 |
Why?
|
Registries | 15 | 2023 | 8091 | 0.610 |
Why?
|
Antibody Specificity | 1 | 2019 | 1095 | 0.600 |
Why?
|
Lung Injury | 1 | 2022 | 436 | 0.600 |
Why?
|
Digestive System Diseases | 1 | 2019 | 147 | 0.590 |
Why?
|
Renal Insufficiency | 1 | 2023 | 804 | 0.590 |
Why?
|
Hospitalization | 11 | 2022 | 10259 | 0.590 |
Why?
|
Pandemics | 11 | 2023 | 8385 | 0.590 |
Why?
|
Gastrointestinal Agents | 1 | 2021 | 494 | 0.580 |
Why?
|
Coronavirus Infections | 5 | 2020 | 3135 | 0.570 |
Why?
|
Pneumonia, Viral | 5 | 2020 | 3242 | 0.570 |
Why?
|
Azathioprine | 4 | 2023 | 354 | 0.560 |
Why?
|
Hepatitis B, Chronic | 1 | 2020 | 393 | 0.540 |
Why?
|
Respiration, Artificial | 7 | 2022 | 2569 | 0.530 |
Why?
|
Infusions, Intravenous | 1 | 2020 | 2274 | 0.530 |
Why?
|
Autoantibodies | 3 | 2020 | 2036 | 0.530 |
Why?
|
Drug Monitoring | 1 | 2021 | 956 | 0.520 |
Why?
|
Orbital Myositis | 2 | 2013 | 20 | 0.520 |
Why?
|
Aged | 45 | 2023 | 163288 | 0.510 |
Why?
|
Orbital Pseudotumor | 2 | 2013 | 42 | 0.510 |
Why?
|
Lung Diseases, Interstitial | 1 | 2023 | 808 | 0.490 |
Why?
|
Physicians, Women | 1 | 2020 | 486 | 0.490 |
Why?
|
Cohort Studies | 18 | 2024 | 40559 | 0.470 |
Why?
|
Lung | 4 | 2021 | 9857 | 0.470 |
Why?
|
Eosinophils | 2 | 2016 | 955 | 0.470 |
Why?
|
Hypersensitivity | 1 | 2022 | 1102 | 0.440 |
Why?
|
Piperidines | 2 | 2021 | 1602 | 0.440 |
Why?
|
Information Dissemination | 2 | 2020 | 1099 | 0.430 |
Why?
|
Adult | 51 | 2023 | 214052 | 0.430 |
Why?
|
Faculty, Medical | 1 | 2020 | 1181 | 0.420 |
Why?
|
Hypergammaglobulinemia | 1 | 2011 | 74 | 0.410 |
Why?
|
Immunity, Cellular | 2 | 2015 | 1607 | 0.400 |
Why?
|
Meningitis | 1 | 2013 | 216 | 0.400 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 5 | 2015 | 693 | 0.400 |
Why?
|
Anti-Infective Agents | 1 | 2019 | 974 | 0.390 |
Why?
|
Lipid Metabolism | 1 | 2019 | 1889 | 0.380 |
Why?
|
Trigeminal Nerve Diseases | 1 | 2011 | 55 | 0.380 |
Why?
|
Paraproteinemias | 1 | 2013 | 246 | 0.370 |
Why?
|
Myocardial Infarction | 2 | 2022 | 11718 | 0.370 |
Why?
|
Gene Regulatory Networks | 1 | 2019 | 1707 | 0.360 |
Why?
|
Sex Factors | 3 | 2021 | 10400 | 0.360 |
Why?
|
Fever | 4 | 2021 | 1616 | 0.360 |
Why?
|
Immune System Diseases | 3 | 2017 | 261 | 0.340 |
Why?
|
Pyrimidines | 2 | 2021 | 2943 | 0.340 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2023 | 2200 | 0.330 |
Why?
|
Disease Progression | 7 | 2023 | 13286 | 0.320 |
Why?
|
Severity of Illness Index | 8 | 2022 | 15535 | 0.320 |
Why?
|
Eye Diseases | 1 | 2013 | 669 | 0.310 |
Why?
|
Lupus Erythematosus, Systemic | 5 | 2023 | 2104 | 0.310 |
Why?
|
Body Composition | 1 | 2017 | 2402 | 0.310 |
Why?
|
Computational Biology | 2 | 2023 | 3519 | 0.310 |
Why?
|
United States | 18 | 2023 | 69872 | 0.300 |
Why?
|
Vaccination | 7 | 2024 | 3279 | 0.290 |
Why?
|
Comorbidity | 7 | 2023 | 10388 | 0.280 |
Why?
|
Immunity, Humoral | 2 | 2023 | 598 | 0.280 |
Why?
|
Antibody Formation | 2 | 2021 | 1402 | 0.270 |
Why?
|
Cause of Death | 5 | 2020 | 3582 | 0.270 |
Why?
|
Autoantigens | 3 | 2020 | 892 | 0.270 |
Why?
|
Diagnosis, Differential | 7 | 2021 | 12961 | 0.270 |
Why?
|
Gout | 2 | 2022 | 573 | 0.270 |
Why?
|
Retrospective Studies | 16 | 2024 | 77460 | 0.260 |
Why?
|
Prednisone | 4 | 2022 | 1574 | 0.250 |
Why?
|
Psoriasis | 2 | 2023 | 902 | 0.240 |
Why?
|
Massachusetts | 3 | 2021 | 8662 | 0.230 |
Why?
|
Hospital Mortality | 1 | 2017 | 5316 | 0.220 |
Why?
|
Pneumocystis carinii | 1 | 2023 | 74 | 0.220 |
Why?
|
Databases, Factual | 2 | 2019 | 7730 | 0.220 |
Why?
|
Arthritis, Psoriatic | 2 | 2023 | 215 | 0.220 |
Why?
|
Systemic Vasculitis | 1 | 2023 | 37 | 0.220 |
Why?
|
Neoplasms | 3 | 2022 | 21696 | 0.210 |
Why?
|
Europe | 2 | 2019 | 3338 | 0.210 |
Why?
|
Recurrence | 5 | 2022 | 8340 | 0.210 |
Why?
|
Leukocyte Count | 2 | 2016 | 1588 | 0.200 |
Why?
|
Glomerulonephritis, Membranous | 2 | 2020 | 86 | 0.200 |
Why?
|
Proportional Hazards Models | 7 | 2021 | 12356 | 0.200 |
Why?
|
Mycophenolic Acid | 2 | 2020 | 343 | 0.200 |
Why?
|
Oral Ulcer | 1 | 2021 | 96 | 0.190 |
Why?
|
Nipecotic Acids | 1 | 2021 | 38 | 0.190 |
Why?
|
T-Lymphocytes, Cytotoxic | 2 | 2020 | 1821 | 0.190 |
Why?
|
Arteritis | 1 | 2023 | 159 | 0.190 |
Why?
|
Incidence | 6 | 2023 | 20952 | 0.190 |
Why?
|
Informatics | 1 | 2021 | 72 | 0.190 |
Why?
|
Churg-Strauss Syndrome | 1 | 2021 | 70 | 0.180 |
Why?
|
Case-Control Studies | 5 | 2023 | 21748 | 0.180 |
Why?
|
Medicare | 4 | 2022 | 6566 | 0.180 |
Why?
|
Arthralgia | 2 | 2021 | 456 | 0.180 |
Why?
|
Methotrexate | 3 | 2023 | 1728 | 0.180 |
Why?
|
Genome-Wide Association Study | 1 | 2019 | 12262 | 0.180 |
Why?
|
CD4-Positive T-Lymphocytes | 4 | 2022 | 4386 | 0.180 |
Why?
|
Colchicine | 1 | 2021 | 244 | 0.180 |
Why?
|
Myositis | 1 | 2022 | 251 | 0.170 |
Why?
|
Exanthema | 2 | 2021 | 501 | 0.170 |
Why?
|
Receptors, Phospholipase A2 | 1 | 2019 | 33 | 0.170 |
Why?
|
Americas | 1 | 2019 | 111 | 0.170 |
Why?
|
Viruses | 1 | 2023 | 375 | 0.170 |
Why?
|
Antibodies, Viral | 4 | 2024 | 3177 | 0.170 |
Why?
|
Blood Sedimentation | 1 | 2019 | 231 | 0.170 |
Why?
|
Risk Factors | 13 | 2023 | 72296 | 0.160 |
Why?
|
Fibrosis | 4 | 2021 | 2029 | 0.160 |
Why?
|
Lymphoma | 2 | 2017 | 1877 | 0.160 |
Why?
|
Entropy | 1 | 2019 | 209 | 0.160 |
Why?
|
Apolipoprotein A-I | 1 | 2019 | 281 | 0.160 |
Why?
|
Inflammation | 2 | 2024 | 10637 | 0.160 |
Why?
|
Fatigue | 2 | 2023 | 1531 | 0.150 |
Why?
|
Apolipoproteins B | 1 | 2019 | 374 | 0.150 |
Why?
|
Drug Therapy, Combination | 5 | 2021 | 6489 | 0.150 |
Why?
|
Neoplasms, Plasma Cell | 1 | 2017 | 36 | 0.150 |
Why?
|
Waiting Lists | 2 | 2019 | 692 | 0.150 |
Why?
|
Temporal Arteries | 1 | 2018 | 128 | 0.150 |
Why?
|
Asia | 1 | 2019 | 609 | 0.150 |
Why?
|
Scleroderma, Systemic | 1 | 2021 | 323 | 0.150 |
Why?
|
Uncertainty | 1 | 2022 | 735 | 0.140 |
Why?
|
Education, Medical, Graduate | 2 | 2020 | 2291 | 0.140 |
Why?
|
Precursor Cells, B-Lymphoid | 1 | 2017 | 98 | 0.140 |
Why?
|
Fatal Outcome | 1 | 2021 | 1851 | 0.140 |
Why?
|
Education, Distance | 1 | 2020 | 251 | 0.140 |
Why?
|
Subclavian Artery | 1 | 2017 | 130 | 0.140 |
Why?
|
Interinstitutional Relations | 1 | 2018 | 241 | 0.140 |
Why?
|
Galectin 3 | 1 | 2018 | 227 | 0.140 |
Why?
|
Logistic Models | 3 | 2020 | 13409 | 0.140 |
Why?
|
Odds Ratio | 4 | 2021 | 9849 | 0.140 |
Why?
|
Antibodies, Monoclonal | 4 | 2024 | 9274 | 0.140 |
Why?
|
Arthritis, Infectious | 1 | 2020 | 367 | 0.140 |
Why?
|
Aniline Compounds | 1 | 2021 | 986 | 0.140 |
Why?
|
Hepatitis B | 1 | 2021 | 695 | 0.130 |
Why?
|
Schools | 2 | 2022 | 1433 | 0.130 |
Why?
|
Neutropenia | 1 | 2020 | 895 | 0.130 |
Why?
|
Lymphocyte Count | 2 | 2016 | 793 | 0.130 |
Why?
|
Aged, 80 and over | 10 | 2024 | 57776 | 0.130 |
Why?
|
Treatment Outcome | 10 | 2018 | 63107 | 0.130 |
Why?
|
Testis | 1 | 2018 | 804 | 0.120 |
Why?
|
Commerce | 1 | 2020 | 592 | 0.120 |
Why?
|
Physicians | 2 | 2023 | 4567 | 0.120 |
Why?
|
Cardiovascular Agents | 1 | 2021 | 850 | 0.120 |
Why?
|
China | 1 | 2020 | 2245 | 0.120 |
Why?
|
Antibody-Producing Cells | 1 | 2014 | 143 | 0.120 |
Why?
|
Cytoplasm | 1 | 2019 | 1536 | 0.120 |
Why?
|
Flow Cytometry | 2 | 2015 | 5974 | 0.120 |
Why?
|
B-Lymphocytes | 3 | 2023 | 4666 | 0.120 |
Why?
|
Biomedical Research | 2 | 2021 | 3309 | 0.120 |
Why?
|
Coronary Aneurysm | 1 | 2016 | 237 | 0.120 |
Why?
|
Immunoglobulin E | 2 | 2018 | 1463 | 0.110 |
Why?
|
International Cooperation | 1 | 2020 | 1420 | 0.110 |
Why?
|
Lymphocytosis | 1 | 2014 | 119 | 0.110 |
Why?
|
Antimalarials | 1 | 2020 | 905 | 0.110 |
Why?
|
Prevalence | 2 | 2023 | 15221 | 0.110 |
Why?
|
Dacryocystitis | 1 | 2013 | 70 | 0.110 |
Why?
|
Research Personnel | 1 | 2018 | 573 | 0.110 |
Why?
|
Cholesterol, HDL | 1 | 2019 | 1813 | 0.110 |
Why?
|
Mentors | 1 | 2018 | 631 | 0.110 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 3873 | 0.110 |
Why?
|
Cross-Sectional Studies | 5 | 2021 | 25039 | 0.110 |
Why?
|
Arterial Occlusive Diseases | 1 | 2017 | 793 | 0.110 |
Why?
|
Myofibroblasts | 1 | 2014 | 222 | 0.110 |
Why?
|
Risk Assessment | 3 | 2023 | 23336 | 0.110 |
Why?
|
Th2 Cells | 1 | 2017 | 1061 | 0.100 |
Why?
|
Myocardial Ischemia | 1 | 2023 | 2148 | 0.100 |
Why?
|
Sensitivity and Specificity | 2 | 2019 | 14723 | 0.100 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 1 | 2013 | 180 | 0.100 |
Why?
|
Antigens, CD | 2 | 2020 | 4026 | 0.100 |
Why?
|
Needs Assessment | 1 | 2018 | 1147 | 0.100 |
Why?
|
Cardiovascular Diseases | 5 | 2020 | 15160 | 0.100 |
Why?
|
Hypertrophy | 1 | 2013 | 569 | 0.100 |
Why?
|
Data Collection | 1 | 2021 | 3339 | 0.100 |
Why?
|
Mucocutaneous Lymph Node Syndrome | 1 | 2016 | 546 | 0.100 |
Why?
|
Leadership | 1 | 2020 | 1357 | 0.100 |
Why?
|
Retreatment | 1 | 2013 | 610 | 0.100 |
Why?
|
Cardiomyopathies | 1 | 2023 | 1912 | 0.100 |
Why?
|
Reproducibility of Results | 2 | 2019 | 19905 | 0.100 |
Why?
|
Premature Birth | 1 | 2023 | 1721 | 0.090 |
Why?
|
Exophthalmos | 1 | 2011 | 97 | 0.090 |
Why?
|
Quality of Life | 2 | 2023 | 12802 | 0.090 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2020 | 2282 | 0.090 |
Why?
|
Lumbar Vertebrae | 1 | 2020 | 1848 | 0.090 |
Why?
|
Consensus | 1 | 2019 | 2960 | 0.090 |
Why?
|
Cholesterol | 1 | 2019 | 2919 | 0.090 |
Why?
|
Interleukin-12 | 2 | 2023 | 580 | 0.090 |
Why?
|
Cholesterol, LDL | 1 | 2019 | 2355 | 0.090 |
Why?
|
Multivariate Analysis | 2 | 2020 | 12244 | 0.090 |
Why?
|
Medicaid | 2 | 2021 | 2737 | 0.090 |
Why?
|
Inflammatory Bowel Diseases | 2 | 2021 | 2428 | 0.090 |
Why?
|
Mesenchymal Stem Cells | 1 | 2020 | 1632 | 0.090 |
Why?
|
Sepsis | 2 | 2020 | 2593 | 0.090 |
Why?
|
Kidney | 2 | 2023 | 7184 | 0.090 |
Why?
|
Kidney Diseases | 1 | 2020 | 2148 | 0.080 |
Why?
|
Chest Pain | 1 | 2016 | 1114 | 0.080 |
Why?
|
Follow-Up Studies | 3 | 2020 | 39052 | 0.080 |
Why?
|
Software | 1 | 2023 | 4441 | 0.080 |
Why?
|
Young Adult | 8 | 2021 | 56429 | 0.080 |
Why?
|
Internet | 1 | 2021 | 3056 | 0.080 |
Why?
|
RNA, Messenger | 1 | 2023 | 13035 | 0.080 |
Why?
|
Lipids | 1 | 2019 | 3307 | 0.080 |
Why?
|
Drug Hypersensitivity | 1 | 2017 | 884 | 0.080 |
Why?
|
Mental Health | 1 | 2022 | 3010 | 0.080 |
Why?
|
Vascular Diseases | 1 | 2016 | 1161 | 0.080 |
Why?
|
Societies, Medical | 1 | 2019 | 3743 | 0.080 |
Why?
|
Tomography, X-Ray Computed | 4 | 2021 | 20130 | 0.080 |
Why?
|
Patient Acceptance of Health Care | 1 | 2021 | 3020 | 0.070 |
Why?
|
Health Expenditures | 1 | 2020 | 2349 | 0.070 |
Why?
|
Retroperitoneal Space | 2 | 2018 | 176 | 0.070 |
Why?
|
Genomics | 1 | 2023 | 5717 | 0.070 |
Why?
|
Hydroxychloroquine | 2 | 2020 | 412 | 0.070 |
Why?
|
Predictive Value of Tests | 1 | 2022 | 15078 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6539 | 0.060 |
Why?
|
Adolescent | 9 | 2023 | 85779 | 0.060 |
Why?
|
Apoptosis | 1 | 2020 | 9724 | 0.060 |
Why?
|
Age Factors | 2 | 2021 | 18373 | 0.050 |
Why?
|
Coronary Artery Disease | 1 | 2023 | 6486 | 0.050 |
Why?
|
Urban Health | 1 | 2005 | 547 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2019 | 9955 | 0.050 |
Why?
|
Endemic Diseases | 1 | 2023 | 182 | 0.050 |
Why?
|
Depression | 1 | 2022 | 7759 | 0.050 |
Why?
|
National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2022 | 62 | 0.050 |
Why?
|
Epitopes, B-Lymphocyte | 1 | 2022 | 87 | 0.050 |
Why?
|
Asthma | 1 | 2021 | 6010 | 0.050 |
Why?
|
Vaccines, Subunit | 1 | 2022 | 168 | 0.050 |
Why?
|
Cooperative Behavior | 2 | 2021 | 1504 | 0.050 |
Why?
|
Homicide | 1 | 2005 | 287 | 0.050 |
Why?
|
Ritonavir | 1 | 2023 | 322 | 0.050 |
Why?
|
Pilot Projects | 3 | 2023 | 8319 | 0.050 |
Why?
|
Students | 2 | 2022 | 1647 | 0.050 |
Why?
|
Prednisolone | 1 | 2022 | 334 | 0.050 |
Why?
|
Coronary Vessels | 2 | 2023 | 3107 | 0.050 |
Why?
|
Phenotype | 1 | 2019 | 16367 | 0.050 |
Why?
|
Wisconsin | 1 | 2021 | 124 | 0.050 |
Why?
|
Survival Rate | 1 | 2015 | 12788 | 0.050 |
Why?
|
Bacteroidetes | 1 | 2021 | 83 | 0.050 |
Why?
|
Filgrastim | 1 | 2020 | 133 | 0.050 |
Why?
|
Nephrosis, Lipoid | 1 | 2020 | 51 | 0.050 |
Why?
|
Antigens, CD19 | 1 | 2023 | 380 | 0.050 |
Why?
|
Hematologic Agents | 1 | 2020 | 39 | 0.050 |
Why?
|
Spondylarthropathies | 1 | 2020 | 14 | 0.050 |
Why?
|
Prospective Studies | 5 | 2024 | 53290 | 0.050 |
Why?
|
Antineoplastic Agents | 1 | 2023 | 13693 | 0.040 |
Why?
|
Quarantine | 1 | 2022 | 170 | 0.040 |
Why?
|
Receptors, Fc | 1 | 2023 | 541 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2023 | 4479 | 0.040 |
Why?
|
Azetidines | 1 | 2020 | 142 | 0.040 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2023 | 780 | 0.040 |
Why?
|
Chloroquine | 1 | 2020 | 279 | 0.040 |
Why?
|
Environment | 1 | 2005 | 1123 | 0.040 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2020 | 297 | 0.040 |
Why?
|
Toll-Like Receptor 4 | 1 | 2022 | 565 | 0.040 |
Why?
|
Azithromycin | 1 | 2020 | 196 | 0.040 |
Why?
|
Vaccines, Synthetic | 1 | 2022 | 634 | 0.040 |
Why?
|
Renal Replacement Therapy | 1 | 2021 | 257 | 0.040 |
Why?
|
Masks | 1 | 2021 | 197 | 0.040 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2022 | 880 | 0.040 |
Why?
|
Immunosorbent Techniques | 1 | 2018 | 184 | 0.040 |
Why?
|
Algorithms | 1 | 2019 | 13882 | 0.040 |
Why?
|
Microcirculation | 1 | 2023 | 1287 | 0.040 |
Why?
|
Coronary Angiography | 2 | 2023 | 4576 | 0.040 |
Why?
|
Virulence | 1 | 2022 | 1333 | 0.040 |
Why?
|
Confusion | 1 | 2020 | 275 | 0.040 |
Why?
|
Asymptomatic Diseases | 1 | 2020 | 551 | 0.040 |
Why?
|
Posterior Leukoencephalopathy Syndrome | 1 | 2018 | 53 | 0.040 |
Why?
|
Time Factors | 2 | 2018 | 40075 | 0.040 |
Why?
|
Muscular Diseases | 1 | 2022 | 555 | 0.040 |
Why?
|
Prognosis | 1 | 2018 | 29060 | 0.040 |
Why?
|
Glomerulosclerosis, Focal Segmental | 1 | 2020 | 357 | 0.040 |
Why?
|
Intensive Care Units | 2 | 2021 | 3680 | 0.040 |
Why?
|
Purines | 1 | 2020 | 594 | 0.040 |
Why?
|
Thrombocytosis | 1 | 2017 | 81 | 0.040 |
Why?
|
Leukocytosis | 1 | 2018 | 247 | 0.040 |
Why?
|
Interleukin-10 | 1 | 2022 | 1200 | 0.040 |
Why?
|
Hematuria | 1 | 2018 | 235 | 0.040 |
Why?
|
Coronary Circulation | 1 | 2023 | 1572 | 0.040 |
Why?
|
Cross-Over Studies | 1 | 2022 | 2029 | 0.040 |
Why?
|
Species Specificity | 1 | 2021 | 2478 | 0.040 |
Why?
|
Epididymis | 1 | 2018 | 227 | 0.040 |
Why?
|
Pregnant Women | 1 | 2021 | 568 | 0.040 |
Why?
|
Immunomodulation | 1 | 2020 | 541 | 0.030 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2020 | 652 | 0.030 |
Why?
|
Submandibular Gland | 1 | 2016 | 86 | 0.030 |
Why?
|
Biological Evolution | 1 | 2022 | 1077 | 0.030 |
Why?
|
Aorta | 1 | 2024 | 2062 | 0.030 |
Why?
|
Accidental Falls | 1 | 2024 | 1062 | 0.030 |
Why?
|
Curriculum | 2 | 2020 | 3605 | 0.030 |
Why?
|
Drugs, Generic | 1 | 2021 | 421 | 0.030 |
Why?
|
Kinetics | 1 | 2024 | 6476 | 0.030 |
Why?
|
Canada | 1 | 2021 | 2065 | 0.030 |
Why?
|
Erythema | 1 | 2017 | 257 | 0.030 |
Why?
|
Residence Characteristics | 1 | 2005 | 2050 | 0.030 |
Why?
|
Databases, Genetic | 1 | 2023 | 1783 | 0.030 |
Why?
|
Interleukin-2 | 1 | 2022 | 1904 | 0.030 |
Why?
|
Lymphocyte Depletion | 1 | 2017 | 608 | 0.030 |
Why?
|
Lymphocyte Activation | 2 | 2018 | 5524 | 0.030 |
Why?
|
Internationality | 1 | 2021 | 1002 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 2020 | 847 | 0.030 |
Why?
|
Sarcoidosis | 1 | 2020 | 506 | 0.030 |
Why?
|
Nasal Septum | 1 | 2016 | 127 | 0.030 |
Why?
|
Immunoglobulins | 1 | 2018 | 881 | 0.030 |
Why?
|
Transforming Growth Factor beta | 1 | 2022 | 2007 | 0.030 |
Why?
|
Antibody Diversity | 1 | 2014 | 74 | 0.030 |
Why?
|
Drug Approval | 1 | 2021 | 742 | 0.030 |
Why?
|
Somatic Hypermutation, Immunoglobulin | 1 | 2014 | 97 | 0.030 |
Why?
|
Biopsy | 2 | 2017 | 6755 | 0.030 |
Why?
|
Pancreas | 1 | 2020 | 1687 | 0.030 |
Why?
|
Arthroscopy | 1 | 2020 | 926 | 0.030 |
Why?
|
Extracellular Matrix | 1 | 2021 | 1741 | 0.030 |
Why?
|
New York City | 2 | 2005 | 710 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2021 | 1584 | 0.030 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2023 | 2917 | 0.030 |
Why?
|
Depressive Disorder | 1 | 2005 | 3747 | 0.030 |
Why?
|
Infant, Newborn | 2 | 2023 | 25628 | 0.030 |
Why?
|
Prostate | 1 | 2020 | 1775 | 0.030 |
Why?
|
Bacteria | 1 | 2023 | 2115 | 0.030 |
Why?
|
Anti-Bacterial Agents | 2 | 2020 | 7182 | 0.030 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2017 | 985 | 0.030 |
Why?
|
Influenza, Human | 1 | 2023 | 1479 | 0.020 |
Why?
|
Program Development | 1 | 2018 | 1316 | 0.020 |
Why?
|
Travel | 1 | 2017 | 788 | 0.020 |
Why?
|
Sulfonamides | 1 | 2020 | 1940 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 2 | 2020 | 35425 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2018 | 2204 | 0.020 |
Why?
|
Clone Cells | 1 | 2014 | 1692 | 0.020 |
Why?
|
Cell Proliferation | 2 | 2018 | 10483 | 0.020 |
Why?
|
Pregnancy | 2 | 2023 | 29144 | 0.020 |
Why?
|
Rural Population | 1 | 2021 | 2207 | 0.020 |
Why?
|
Magnetic Resonance Angiography | 1 | 2017 | 1443 | 0.020 |
Why?
|
Pyrazoles | 1 | 2020 | 1972 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 4933 | 0.020 |
Why?
|
Anaphylaxis | 1 | 2017 | 746 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 2020 | 3799 | 0.020 |
Why?
|
Qualitative Research | 1 | 2018 | 2682 | 0.020 |
Why?
|
T-Lymphocyte Subsets | 1 | 2017 | 1837 | 0.020 |
Why?
|
Outpatients | 1 | 2017 | 1487 | 0.020 |
Why?
|
Venous Thromboembolism | 1 | 2021 | 1671 | 0.020 |
Why?
|
Substance-Related Disorders | 1 | 2005 | 4257 | 0.020 |
Why?
|
Skin Diseases | 1 | 2017 | 1066 | 0.020 |
Why?
|
Acute Kidney Injury | 1 | 2021 | 1968 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2018 | 6621 | 0.020 |
Why?
|
Gastrointestinal Diseases | 1 | 2017 | 1170 | 0.020 |
Why?
|
Boston | 1 | 2021 | 9312 | 0.020 |
Why?
|
Public Health | 1 | 2021 | 2602 | 0.020 |
Why?
|
Anemia | 1 | 2017 | 1503 | 0.020 |
Why?
|
Research Design | 1 | 2022 | 5984 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2018 | 3778 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2017 | 2725 | 0.020 |
Why?
|
Survival Analysis | 1 | 2019 | 10252 | 0.020 |
Why?
|
Ultrasonography | 1 | 2018 | 5984 | 0.020 |
Why?
|
Lymph Nodes | 1 | 2016 | 3476 | 0.020 |
Why?
|
Child | 2 | 2023 | 77709 | 0.010 |
Why?
|
Coronary Disease | 1 | 2019 | 6077 | 0.010 |
Why?
|
Pain | 1 | 2018 | 4988 | 0.010 |
Why?
|
Electrocardiography | 1 | 2016 | 6442 | 0.010 |
Why?
|
Cytokines | 1 | 2016 | 7323 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2014 | 11366 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2017 | 4468 | 0.010 |
Why?
|
Demography | 1 | 2005 | 1655 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2017 | 5321 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2017 | 18034 | 0.010 |
Why?
|
Child, Preschool | 1 | 2021 | 41005 | 0.010 |
Why?
|
Signal Transduction | 1 | 2021 | 23404 | 0.010 |
Why?
|
Animals | 2 | 2022 | 168768 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2005 | 7785 | 0.010 |
Why?
|
Mice | 1 | 2017 | 81201 | 0.010 |
Why?
|